https://ogma.newcastle.edu.au/vital/access/ /manager/Index en-au 5 Open-source, fully-automated hybrid cardiac substructure segmentation: development and optimisation https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:53327 Wed 28 Feb 2024 16:29:04 AEDT ]]> Cancer Therapies and Cardiomyocyte Viability: Which Drugs are Directly Cardiotoxic? https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:55729 Wed 19 Jun 2024 09:47:51 AEST ]]> Incidence, time of occurrence and response to heart failure therapy in patients with anthracycline cardiotoxicity https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:32965 Wed 19 Jan 2022 15:18:41 AEDT ]]> Global Cardio Oncology Registry (G-COR): Registry Design, Primary Objectives, and Future Perspectives of a Multicenter Global Initiative https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:54028 Wed 13 Mar 2024 07:47:53 AEDT ]]> Anthracycline-induced cardiotoxicity: time to focus on cardioprotection again https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:36732 Thu 02 Jul 2020 09:45:43 AEST ]]> Calcium channel blockers https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:24543 Sat 24 Mar 2018 07:11:34 AEDT ]]> Baseline cardiovascular risk assessment in cancer patients scheduled to receive cardiotoxic cancer therapies: a position statement and new risk assessment tools from the Cardio-Oncology Study Group of the Heart Failure Association of the European Society of Cardiology in collaboration with the International Cardio-Oncology Society https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:44599 Mon 17 Oct 2022 16:08:38 AEDT ]]> Cardiotoxicity of radiation therapy: mechanisms, management, and mitigation https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:42763 Fri 02 Sep 2022 09:01:20 AEST ]]>